Headlines about GTX (NASDAQ:GTXI) have trended somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. GTX earned a news impact score of 0.06 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 44.9647806574889 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

GTX (GTXI) opened at $12.95 on Thursday. GTX has a fifty-two week low of $2.73 and a fifty-two week high of $13.35.

GTX (NASDAQ:GTXI) last issued its earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.25). research analysts anticipate that GTX will post -1.61 earnings per share for the current year.

Several research analysts recently issued reports on GTXI shares. Stifel Nicolaus started coverage on shares of GTX in a report on Thursday, November 9th. They set a “buy” rating for the company. Robert W. Baird started coverage on shares of GTX in a report on Tuesday, November 21st. They set an “outperform” rating and a $17.00 target price for the company.

TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect GTX (GTXI) Share Price” was first posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/12/14/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-gtx-gtxi-share-price.html.

About GTX

GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).

Insider Buying and Selling by Quarter for GTX (NASDAQ:GTXI)

Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.